AKT1 and neoplasm: PI3K pathway inhibitors did not decrease tumor growth in the two AKT1-mutated models, but HBCx-2 PDX responded to the mTOR inhibitor AZD2014 (TGI=86%, p=0.0001) and the dual inhibitor (mTOR and PIK3Ca) (TGI =70%, p=0.001).